Skip to main content
Figure 1 | Retrovirology

Figure 1

From: Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

Figure 1

Differential intracellular drug retention. JT-CCR5 cells were exposed to drug (A- TDF; B- IQP-0528; C- DPV; D- MVC; E- PIE12; F- TDF + IQP-0528) in complete medium for 24 h prior to challenge with approximately 103 TCID50 HIV-1Ba-L. Virus challenge was performed in the presence of drug (black lines, closed squares), after washing with serum-free medium (hatched black lines, open triangles) or after washing with serum-free medium containing 10% seminal plasma (SP) (grey lines, open circles). HIV replication was assessed by measuring p24 antigen in culture supernatants 6 days post-infection. Data are presented as percent inhibition relative to cells challenged in the absence of treatment and are means ± SEM obtained from at least three independent experiments where each condition was tested in triplicate, except where noted # (one experiment).

Back to article page